Bacopa monniera Attenuates Scopolamine-Induced Impairment of Spatial Memory in Mice
Figure 2
Effect of B. monniera on scopolamine-induced retrograde amnesia. During retrieval trials, each value represents mean ± SEM. Control group shows significant enhancement in time spent in target quadrant (Q2) as compared to other quadrant which suggests normal retrieval of memory. The 5% Tween 80 does no alter normal retrieval since this group indicates more time spent in target quadrant that is not different from control group. (a) Scopolamine at dose of 0.5 mg kg−1 i.p., but not at 0.1 mg kg−1 i.p. dose, significantly reduced the time spent in target quadrant by producing retrograde amnesia. (b) Bacopa monniera (120 mg kg−1 oral) does not alter normal retrieval as compared to control and 5% Tween 80. Bacopa monniera at 120 mg kg−1 oral increases the time spent target quadrant in scopolamine treated mice as compared to scopolamine alone treated mice and it, therefore, attenuates scopolamine (0.5 mg kg−1 i.p.)-induced retrograde amnesia. “f" indicates P < .05 versus time spent in other quadrants, that is, Q1, Q3 and Q4, here data were analyzed using one-way ANOVA followed by Dunnett’s test. “g" indicates significance at P < .05 versus control group’s time spent in target quadrant (Q2). “h" indicates significance at P < .05 versus 5% Tween 80 group’s time spent in target quadrant (Q2). “i" indicates significance at P < .05 versus scopolamine group’s time spent in target quadrant (Q2). Here, data were analyzed using one-way ANOVA followed by LSD test.
